Clinical Trial Details

< Previous Trial     Next Trial >
Study ID CHUBX 2008/20
Investigator
CLERMONT-GALLERANDE Henri, MCU-PH,   University Hospital, Bordeaux
PEREZ Paul, PH,   Bordeaux University Hospital
Title Prognostic Evaluation of 18fmiso Pet-ct in Head and Neck Cancer
Conditions Cancer of Head and Neck
Head and Neck Neoplasms
Interventions Radiation: Positon Emission Tomography using 18F-FMISO
Phase N/A
Purpose Head and neck cancer is the sixth most frequent cancer worldwide, excluding lymphomas and skin cancer. If 18FDG PET is considered today as a standard tool in patients with head and neck squamous cell carcinoma (HNSCC) not only for tumoral or nodal staging but also for assessment of distant metastases and synchronous second primary malignancies, hypoxia is one of the most important prognostic factors in radiotherapy of this type of tumors. The only gold standard method for direct determination of oxygen tension is based on using oxygen electrodes showing a good relation with clinical outcome but complex in its realisation. So, PET using 18F-FMISO has been described to be useful for the non invasive assessment of hypoxia in cancer. Especially in France, the use of this radiotracer is very limited and there is no standardised methodology to acquire and quantify 18F-FMISO signal. So there is a need for a rigorous evaluation of this PET tracer. In another way, it could be a very useful tool for evaluation of new therapies and modification of volumes in radiotherapy.
Eligibility Ages Eligible: 18 Years
Genders Eligible:  Both
Accepts Healthy Volunteers:  No
Inclusion Criteria:
  • Patients over 18
  • Patients presenting a squamous cell head and neck carcinoma proposed for a radical treatment consisting in conformational radiotherapy with or without chemotherapy or associated targeted therapy
  • Signed informed consent
Exclusion Criteria:
  • Patients with distant metastases known before inclusion
  • Patients suffering of a second cancer or treated before by radiotherapy in the tumour site.
  • Pregnancy
Study Location
Contact

Information objtained from ClinicalTrials.gov, on 10/2/2014. For additional information about this and other clinical trials, visit http://clinicaltrials.gov.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01235052


Back to Search Results